Abstract |
Health care personnel who received the hepatitis B vaccine ( Heptavax-BR, MSD) were followed for persistence of hepatitis B surface antibody (anti-HBs). Response occurred in 135/146 (92.5 percent) vaccinees. Loss of anti-HBs (less than 72 RIA units; 10 S/N) occurred in 35.9 percent during the 36-month surveillance. Stepwise discriminant analysis found age and magnitude of initial antibody level, but not weight-height index, to be predictive of antibody loss over the 36 months. Twenty-four of 27 employees (88.9 percent) who lost anti-HBs responded to a fourth vaccine dose. In contrast, three of eight initial non-responders (37.5 percent) developed antibody after a fourth vaccine dose.
|
Authors | M T Pasko, T R Beam Jr |
Journal | American journal of public health
(Am J Public Health)
Vol. 80
Issue 5
Pg. 590-3
(May 1990)
ISSN: 0090-0036 [Print] United States |
PMID | 2139306
(Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S.)
|
Chemical References |
- Hepatitis B Antibodies
- Hepatitis B Vaccines
- Viral Hepatitis Vaccines
|
Topics |
- Adult
- Age Factors
- Discriminant Analysis
- Female
- Health Workforce
- Hepatitis B
(immunology, prevention & control)
- Hepatitis B Antibodies
(blood)
- Hepatitis B Vaccines
- Humans
- Immunization, Secondary
- Male
- Radioimmunoassay
- Vaccination
- Viral Hepatitis Vaccines
|